Recent News

• 06.02.2025 - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.02.2025 - Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 05.30.2025 - Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference
• 05.30.2025 - Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference
• 05.15.2025 - Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
• 05.15.2025 - Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
• 05.14.2025 - Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
• 05.14.2025 - UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
• 05.14.2025 - Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
• 05.12.2025 - Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million

Recent Filings

• 05.27.2025 - 144 Report of proposed sale of securities
• 05.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2025 - 8-K Current report
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 144 Report of proposed sale of securities
• 05.15.2025 - EX-99.1 EX-99.1
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.15.2025 - 8-K Current report